bullish
Symbio Pharma (4582 JP) - Gross Margin Expansion Led Operational Turnaround in 2021
140 Views05 Apr 2018 19:21
2020 – an inflection point for Symbio
Treakisym (bendamustine), Symbio’s only revenue driver currently, is marketed by Eisai in Japan for r/r NHL....
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 17-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Symbio Confirms Treakisym’s In-House Commercialization Post Patent Expiration in 2020e16 Oct 2018
- Symbio Pharma (4582 JP) - Gross Margin Expansion Led Operational Turnaround in 202105 Apr 2018
- Japan Pharmaceutical - Sector Overview29 Mar 2018
- Takeda - Brigantinib Gets FDA Approval04 May 2017
x